Norinchukin Bank The Has $14.06 Million Stake in Danaher Co. (DHR)

Norinchukin Bank The lifted its position in Danaher Co. (NYSE:DHR) by 2.3% in the fourth quarter, Holdings Channel reports. The institutional investor owned 151,475 shares of the conglomerate’s stock after purchasing an additional 3,445 shares during the period. Norinchukin Bank The’s holdings in Danaher were worth $14,060,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently modified their holdings of the company. Point72 Asset Management L.P. raised its stake in Danaher by 276.8% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,626,865 shares of the conglomerate’s stock valued at $225,332,000 after purchasing an additional 1,929,751 shares during the last quarter. BlackRock Inc. raised its stake in Danaher by 4.6% during the 4th quarter. BlackRock Inc. now owns 40,984,366 shares of the conglomerate’s stock valued at $3,804,169,000 after purchasing an additional 1,789,474 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its stake in Danaher by 16,410.0% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,485,901 shares of the conglomerate’s stock valued at $125,395,000 after purchasing an additional 1,476,901 shares during the last quarter. Findlay Park Partners LLP raised its stake in Danaher by 52.9% during the 3rd quarter. Findlay Park Partners LLP now owns 4,117,348 shares of the conglomerate’s stock valued at $353,186,000 after purchasing an additional 1,425,000 shares during the last quarter. Finally, Koch Industries Inc. raised its stake in Danaher by 29,127.3% during the 2nd quarter. Koch Industries Inc. now owns 1,404,665 shares of the conglomerate’s stock valued at $1,388,000 after purchasing an additional 1,399,859 shares during the last quarter. Institutional investors and hedge funds own 77.05% of the company’s stock.

Danaher Co. (NYSE:DHR) opened at $97.54 on Monday. Danaher Co. has a one year low of $78.97 and a one year high of $104.82. The stock has a market cap of $67,946.36, a price-to-earnings ratio of 24.20, a PEG ratio of 2.05 and a beta of 1.04. The company has a quick ratio of 1.05, a current ratio of 1.43 and a debt-to-equity ratio of 0.39.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.16 by $0.03. Danaher had a net margin of 13.60% and a return on equity of 11.36%. The company had revenue of $5.09 billion during the quarter, compared to analysts’ expectations of $4.97 billion. During the same quarter in the prior year, the company posted $1.05 EPS. The business’s revenue was up 10.9% on a year-over-year basis. sell-side analysts forecast that Danaher Co. will post 4.37 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 26th. Stockholders of record on Friday, December 29th were paid a $0.14 dividend. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.57%. The ex-dividend date was Thursday, December 28th. Danaher’s dividend payout ratio is 15.86%.

In other news, EVP William K. Daniel sold 131,066 shares of the company’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $102.05, for a total value of $13,375,285.30. Following the sale, the executive vice president now owns 270,523 shares of the company’s stock, valued at approximately $27,606,872.15. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Daniel L. Comas sold 62,989 shares of the company’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $101.96, for a total transaction of $6,422,358.44. Following the completion of the sale, the chief financial officer now directly owns 227,805 shares in the company, valued at approximately $23,226,997.80. The disclosure for this sale can be found here. In the last 90 days, insiders sold 237,043 shares of company stock valued at $24,194,886. Corporate insiders own 12.20% of the company’s stock.

Several research firms recently commented on DHR. Barclays began coverage on shares of Danaher in a research note on Thursday. They set an “overweight” rating and a $110.00 target price for the company. Argus upped their target price on shares of Danaher from $100.00 to $115.00 and gave the company a “buy” rating in a research note on Thursday, February 1st. Royal Bank of Canada reiterated a “hold” rating and set a $98.00 target price on shares of Danaher in a research note on Wednesday, January 31st. Stifel Nicolaus upped their target price on shares of Danaher from $110.00 to $115.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. Finally, Morgan Stanley upped their target price on shares of Danaher from $103.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday, January 31st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $100.68.

TRADEMARK VIOLATION WARNING: “Norinchukin Bank The Has $14.06 Million Stake in Danaher Co. (DHR)” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://stocknewstimes.com/2018/02/19/norinchukin-bank-the-has-14-06-million-stake-in-danaher-co-dhr.html.

Danaher Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply